This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Captopril

From Proteopedia

Revision as of 16:50, 28 November 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Rosiglitazone, also known as Avandia

Drag the structure with the mouse to rotate

Better Known as: Capoten

  • Marketed By: Bristol-Myers Squibb
  • Major Indication: Hypertension & Congestive Heart Failure
  • Drug Class: ACE Inhibitor
  • Date of FDA Approval (Patent Expiration): 1981 (1996)
  • 2009 Sales: N/A
  • Why You Should Care: It was the first Angiotensin-Converting Enzyme Inhibitor. Was one of the earliest successes of Structure-Based drug design.
  • The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Mechanism of Action

Pharmacokinetics

ACE-Inhibitor Pharmacokinetics Comparison at Equivalent Dosages
Parameter Captopril Lisinopril Enalapril Benazepril
Tmax (hr)
Cmax (ng/ml)
Bioavailability (%)
Protein Binding (%) 96.7
T1/2 (hr)
AUC (ng/ml/hr)
IC50 (nM)
Equivalent Dosage (mg)
Metabolism

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Captopril"
Personal tools